0000769993-20-000004.txt : 20200106
0000769993-20-000004.hdr.sgml : 20200106
20200106191416
ACCESSION NUMBER: 0000769993-20-000004
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200102
FILED AS OF DATE: 20200106
DATE AS OF CHANGE: 20200106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jones Adrian M
CENTRAL INDEX KEY: 0001359316
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36571
FILM NUMBER: 20511671
MAIL ADDRESS:
STREET 1: C/O GOLDMAN, SACHS & CO.
STREET 2: 85 BROAD STREET
CITY: NEW YORK
STATE: NY
ZIP: 10004
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: T2 Biosystems, Inc.
CENTRAL INDEX KEY: 0001492674
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 204827488
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-457-1200
MAIL ADDRESS:
STREET 1: 101 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
ownershipdoc01022020024513.xml
X0306
4
2020-01-02-05:00
false
0001492674
T2 Biosystems, Inc.
TTOO
0001359316
Jones Adrian M
C/O GOLDMAN SACHS & CO. LLC
200 WEST STREET
NEW YORK
NY
10282
true
false
false
false
Common Stock
2020-01-02-05:00
4
A
false
34188
0
A
4270641
I
See footnotes
Non-Qualified Stock Option (Right to Buy)
8.92
2026-03-09-04:00
Common Stock
66176
66176
I
See footnotes
Stock Option (Right to Buy)
1.54
2029-06-07-04:00
Common Stock
22000
22000
I
See footnotes
The Reporting Person is a managing director of Goldman Sachs & Co. LLC ("Goldman Sachs"). Goldman Sachs is a subsidiary of The Goldman Sachs Group, Inc. ("GS Group"). The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any.
The 34,188 shares of common stock, par value $0.001 per share (the "Common Stock"), were granted pursuant to T2 Biosystems, Inc.'s (the "Company") Amended and Restated 2014 Incentive Award Plan under the Company's Non-Employee Director Compensation Program (the "Plan"), consisting of 34,188 restricted stock units granted to the Reporting Person in his capacity as a director of the Company. The grant of 34,188 restricted stock units shall become fully vested on January 2, 2021, subject to the Reporting Person continuing in service on the Company's board of directors through such vesting date. Each restricted stock unit represents a contingent right to receive one share of the Company's Common Stock. The Reporting Person has an understanding with GS Group pursuant to which he holds such securities for the benefit of GS Group.
GS Group may be deemed to beneficially own 4,270,641 shares of common stock by reason of 34,188 restricted stock units that were granted to the Reporting Person pursuant to the Plan. GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of common stock of the Company by reason of the direct beneficial ownership of common stock by certain investment entities (the "GS Funds") because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs beneficially owns directly and GS Group may be deemed to beneficially own indirectly 29,216 shares of common stock.
The options to purchase 66,176 shares of common stock of the Company were granted to the Reporting Person in his capacity as a director of the Company pursuant to the Plan. The options vested on March 9, 2019. The Reporting Person has an understanding with GS Group pursuant to which he holds such options for the benefit of GS Group.
The options to purchase 22,000 shares of common stock of the Company were granted to the Reporting Person, pursuant to Plan on June 7, 2019 in his capacity as a director of the Company. The options vest and become exercisable in twelve substantially equal monthly installments commencing on June 7, 2019.The Reporting Person has an understanding with GS Group pursuant to which he holds such options for the benefit of GS Group.
/s/ Jamison Yardley, Attorney-in-fact
2020-01-06-05:00